Enlarging the scope of managing benign prostatic hyperplasia: Addressing sexual function and quality of life

International Journal of Clinical Practice

Volumn 59, Issue 5, 2005, Pages 579-590

  Martin, D J ^a   Mulhall, John P ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Erectile dysfunction; Lower urinary tract symptoms; Prostate

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE; CYCLIC GMP; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; HERBACEOUS AGENT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NITRIC OXIDE; NORADRENALIN; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PLACEBO; PLANT EXTRACT; PROSTAGLANDIN E; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; SUBSTANCE P; TAMSULOSIN; TERAZOSIN; VASOACTIVE INTESTINAL POLYPEPTIDE; STEROID 5ALPHA REDUCTASE;

ASTHENIA; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERECTILE DYSFUNCTION; FATIGUE; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; LASER SURGERY; LIBIDO DISORDER; META ANALYSIS; NOCTURIA; NONHUMAN; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROGRADE EJACULATION; REVIEW; RHINITIS; SABAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT DISEASE; AGED; CATHETER ABLATION; DRUG ANTAGONISM; IMPOTENCE; MALE; MIDDLE AGED; PROSTATECTOMY;

AGED; CATHETER ABLATION; HUMANS; IMPOTENCE; LASER SURGERY; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 27144532797     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00531.x     Document Type: Review

References (101)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
2. Collins MM, Meigs JB, Barry MJ, Walker-Corkery E, Giovannucci E, Kawachi I. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002; 167: 1363-6.
3. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999; 162: 376-82.
4. Meigs JB, Mohr B, Barry MJ, Collins MM, Mckinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935-44.
5. Barry MJ, Batista JE, Donovan J et al. Measuring the symptoms and health impact of benign prostatic hyperplasia and its treatments. In: Chatelain C, Denis L, Foo KT, Khoury S, McConnell J, eds. Benign Prostatic Hyperplasia, 5th edn. UK: Health Publication Ltd, 2001: 203-20.
6. Algaba F. Pathophysiology of benign prostatic hyperplasia. Eur Urol 1994; 25 (Suppl. 1): 3-5.
7. Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl 1996; 6: 67-73.
8. Mcneal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15: 340-5.
9. Abrams P. New words for old: lower urinary tract symptoms for 'prostatism' [editorial]. BMJ 1994; 308: 929-30.
10. 1 adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546-51.
11. 1D- adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999; 161: 635-40.
12. Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995; 22: 237-46.
13. Wein AJ, Rovner ES. Assessing outcomes following treatment for benign prostatic hyperplasia. AUA Update Series 1999; 5: 34-9.
14. Birkhoff JD, Wiederhorn AR, Hamilton ML, Zinsser HH. Natural history of benign prostatic hypertrophy and acute urinary retention. Urology 1976; 7: 48-52.
15. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997; 31: 272-80.
16. Garraway WM, Kirby RS. Benign prostatic hyperplasia: effects on quality of life and impact on treatment decisions. Urology 1994; 44: 629-36.
17. Baniel J, Israilov S, Shmueli J, Segenreich E, Livne PM. Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy. Eur Urol 2000; 38: 53-8.
18. Burger B, Weidner W, Altwein JE. Prostate and sexuality: an overview. Eur Urol 1999; 35: 177-84.
19. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36.
20. Rosen R, O'Leary M, Altwein J et al. LUTS and male sexual dysfunction: the multi-national survey of the aging male (MSAM-7). American Urological Association Annual Meeting; Orlando, FL; May 25-30, 2002.
21. Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I. The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. Br J Urol 1998; 82: 842-6.
22. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-44.
23. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-11.
24. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
25. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75: 191-236.
26. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989; 321: 1648-59.
27. Wang R, Higuera TR, Sikka SC et al. Penile erections induced by vasoactive intestinal peptide and sodium nitroprusside. Urol Res 1993; 21: 75-8.
28. Iwanage T, Hanyu S, Tamaki M. VIP and other bioactive substances involved in penile erection. Biomed Res 1992; 2: 71.
29. Levin RM, Wein AJ. Adrenergic alpha receptors outnumber beta receptors in human penile corpus cavernosum. Invest Urol 1980; 18: 225-6.
30. 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. J Urol 1995; 153: 222-7.
31. Brindley GS. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry 1983; 143: 332-7.
32. Hedlund H, Andersson KE. Comparison of the responses to drugs acting on adrenoreceptors and muscarinic receptors in human isolated corpus cavernosum and cavernous artery. J Auton Pharmacol 1985; 5: 81-8.
33. Saenz de Tejada I, Kim N, Lagan I, Krane RJ, Goldstein I. Regulation of adrenergic activity in penile corpus cavernosum. J Urol 1989; 142: 1117-21.
34. Chang S, Hypolite JA, Wein AJ, Chacko S, Disanto ME. The effect of bladder outlet obstruction on rabbit corpus cavernosum smooth muscle contractility. J Urol 2001; 165: 228. [abstract 940]
35. Calvert RC, Khan MA, Thompson CS, Dashwood MR, Mikhailidis DP, Morgan RJ. Alternations in nitric oxide signalling provides insight into the pathophysiology of erectile dysfunction associated with benign prostatic hyperplasia. J Urol 2001; 165:228. [abstract 941]
36. Goldstein I. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. Int J Impot Res 2000; 12 (Suppl. 1): S75-S80.
37. Becker AJ, Stief CG, Machtens S et al. Oral phentolamine as treatment for erectile dysfunction. J Urol 1998; 159: 1214-6.
38. Schwinn DA. The role of α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001; 88 (Suppl. 2): 27-34.
39. Mckeage K, Plosker GL. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62: 633-53.
40. Lee M. Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother 2000; 34: 188-99.
41. Lepor H, Auerbach S, Puras-Baez A et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74.
42. Lieber MM. Pharmacologic therapy for prostatism. Mayo Clin Proc 1998;73: 590-6.
43. Prescribing information: Hytrin® (terazosin hydrochloride) capsules. In: Physicians' Desk Reference, 55th edn. Montvale, NJ, USA: Medical Economics Co., 2001: 461-4.
44. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol 2000; 163: 1134-7.
45. Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994; 44: 46-51.
46. Fawzy A, Braun K, Lewis GP et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9.
47. Prescribing information: Cardura® (doxazosin mesylate) tablets. In: Physicians' Desk Reference, 55th edn. Montvale, NJ: Medical Economics Co., 2001: 2473-7.
48. Narayan P, Tewari A, Members of the United States 93-01 Study Group. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 1701-6.
49. 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruc-tion (symptomatic BPH). Eur Urol 1996; 29: 145-54.
50. Prescribing information: Flomax® (tamsulosin hydrochloride) capsules. In: Physicians' Desk Reference, 55th edn. Montvale, NJ: Medical Economics Company, 2002: 974-7.
51. Debruyne FMJ, Van der Poel HG. Clinical experience in Europe with uroselective Hi-Antagonists. Eur Urol 1999; 36 (Suppl. 1): 54-8.
52. Höfner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ for the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335-41.
53. 1- blocker alfuzosin in symptomatic patients with BPH. Eur Urol 2000; 37: 680-6.
54. Roehrborn CG for the Alfus Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 953-9.
55. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P, the Alforti Study Group. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000; 37: 306-13.
56. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, the BPH-ALF Group. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457-63.
57. Lukacs B, Grange JC, Comet D, McCarthy C. History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur Urol 2000; 37: 183-90.
58. Sánchez-Chapado M, Guil M, Alfaro V, Badiella L, Fernández-Hernando N. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. Eur Urol 2000; 37: 421-7.
59. Lukacs B, Leplège A, Thibault P, Jardin A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996; 48: 731-40.
60. Rittmaster RS. Finasteride. N Engl J Med 1994; 330: 120-5.
61. Gormley GJ, Stoner E, Bruskewitz RC et al. for the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-91.
62. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31-7.
63. Lepor H, Williford WO, Barry MJ et al. for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533-9.
64. Roehrborn CG. Meta-analysis of randomized clinical trials of finasteride. Urology 1998; 51 (Suppl. 4A): 46-9.
65. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405.
66. Debruyne FMJ, Jardin A, Colloi D et al. on behalf of the European ALFIN Study Group. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 34: 169-75.
67. Mtops Research Group. The impact of medical therapy on the clinical progression of BPH: results of the MTOPS trial [abstract 1042]. Benign Prostatic Hyperplasia (BPH): Medical and Hormonal Therapy. American Urological Association Annual Meeting; Orlando, Florida; May 28, 2002.
68. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5-α-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000; 37: 367-80.
69. Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998; 104: 170-8.
70. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 1996; 48: 12-20.
71. Weisser H, Tunn S, Behnke B, Krieg M. Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia. Prostate 1996; 28: 300-6.
72. Carraro JC, Raynaud J-P, Koch G et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996; 29: 231-40.
73. Plosker GL, Brogden RN. Serenoa repens (Permixon®). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996; 9: 379-95.
74. Wilt TJ, Ishani A, Stark G, Macdonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia. A systematic review. JAMA 1998; 280: 1604-9.
75. Lowe F, Robertson C, Roehrborn C, Boyle P. Meta-analysis of clinical trails of permixon. J Urol 1998; 159 (5 Suppl): 257. [abstract 986]
76. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-9.
77. Hakenberg OW, Pinnock CB, Marshall VR. Does evaluation with the International Prostate Symptom Score predict the outcome of transurethral resection of the prostate? J Urol 1997; 158: 94-9.
78. Nudell DM, Cattolica EV. Transurethral prostatectomy: an update. AUA Update Series 2000; 5: 34-9.
79. Roehrborn CG. Standard surgical interventions: TURP/TUIP/OPSU. In: Kirby R, Mcconnell J, Fitzpatrick J, Roehrborn C, Boyle P, eds. Textbook of Benign Prostatic Hyperplasia. Oxford: ISIS Medical Media, 1996: 341-78.
80. O'Leary MP. Quality of life and sexuality: methodological aspects. Eur Urol 2001; 40 (Suppl. 3): 13-8.
81. Mishriki SF, Cohen NP, Mawas A, Gibbons B. TURP can improve your sex life. J Urol 2001; 165: 366. [abstract 1501]
82. Riehmann M, Knes JM, Heisey D, Madsen PO, Bruskewitz RC. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995; 45: 768-75.
83. Oesterling JE. Retropubic and suprapubic prostatectomy. In: Walsh PC, ed. Campbell's Urology, 7th edn. Philadelphia: W.B. Saunders, 1998: 1529-41.
84. Bryan NP, Hastie KJ, Chapple CR. Randomised prospective trial of contact laser prostatectomy (CLAP) versus visual laser coagulation of the prostate (VLAP) for the treatment of benign prostatic hyperplasia. 2-year follow-up. Eur Urol 2000; 38: 265-71.
85. Chilton CP, Mundy IP, Wiseman O. Results of holmium laser resection of the prostate for benign prostatic hyperplasia. J Endourol 2000; 14: 533-4.
86. Gilling PJ, Mackey M, Cresswell M, Kennet K, Kabalin JN, Fraundorfer MR. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year followup. J Urol 1999; 162: 1640-4.
87. Gilling PJ, Kennett KM, Fraundorfer MR. Holmium laser enucleation of the prostate for glands larger than 100 g: an endourologic alternative to open prostatectomy. J Endourol 2000; 14: 529-31.
88. Le Due A, Gilling PJ. Holmium laser resection of the prostate. Eur Urol 1999;35: 155-60.
89. Simopoulos DN, Blute ML. Transurethral microwave thermotherapy: an update on technology and clinical outcomes. AUA Update Series 2001; 5: 58-63.
90. Dahlstrand C, Waiden M, Geirsson G, Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br J Urol 1995; 76: 614-8.
91. Beduschi MC, Oesterling JE. Transurethral needle ablation of the prostate: a minimally invasive treatment for symptomatic benign prostatic hyperplasia. Mayo Clin Proc 1998; 73: 696-701.
92. Schulman CC, Zlotta AR. Transurethral needle ablation (TUNA™) of the prostate: clinical experience with two years follow-up in patients with benign prostatic hyperplasia (BPH). Eur Urol 1996; 30 (Suppl. 2): 263. [abstract 985]
93. Bruskewitz R, Issa MM, Roehrborn CG et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998; 159: 1588-93.
94. Roehrborn C, van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once daily: a pooled analysis of three double blind placebo controlled studies. Submitted to the 17th Congress of the European Association of Urology; Birmingham, UK; February 23-26, 2002.
95. Fowler FJ Jr, Barry MJ. Quality of life assessment for evaluating benign prostatic hyperplasia treatments. An example of using a condition-specific index. Eur Urol 1993; 24 (Suppl. 1): 24-7.
96. 1A-Adrenergic receptors in the isolated human prostate. Pharmacology Communications 1994; 4: 181-8.
97. Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 1993; 22: 301-7.
98. Andersson KE. α-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists. World J Urol 2002; 19: 390-6.
99. 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-67.
100. Rudner XL, Berkowitz DE, Booth JV et al. Subtype specific regulation of human vascular alpha (l)-adrenergic receptors by vessel bed and age. Circulation 1999; 100: 2336-43.
101. 1A-adrenoceptor antagonist, does not improve lower urinary tract symptoms in men with benign prostatic hyperplasia [Available at: http://www.aua.agora.com/abstractviewer/av_view.asp. Last updated: 2002; Accessed: 6 Aug 2002.]